On behalf of the ASTCT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Amrita Krishnan, MD, and William A. Wood, MD.

Question Title

* 1. In the multicenter phase II trial by Miklos and colleagues1, ibrutinib induced sustained responses in patients with steroid-resistant chronic graft-versus-host disease.

What is the reported overall response rate in the study?

Question Title

* 2. What proportions of patients with chronic graft-versus-host disease achieve complete or partial response with no secondary systemic treatment or recurrent malignancy at 1 year after initial treatment of chronic graft-versus-host disease?

Question Title

* 3. National Institute of Health 2014 criteria is widely accepted for diagnosis and scoring of chronic graft-versus-host disease.

Which statement about these criteria is CORRECT

Question Title

* 4. Approximately, what percentage of abnormalities in at least 1 organ is unequivocally attributed to causes other than chronic graft-versus-host disease?

Question Title

* 5. What is the 2-year cumulative incidence of chronic graft-versus-host disease that requires systemic therapy?

T